ASX and NASDAQ listed biotechnology company Immutep Limited (“Immutep“ or the “Company“), is pleased to announce that it has today successfully completed a A$29.6 million share placement to professional, institutional and sophisticated investors (Placement).
Immutep CEO Marc Voigt said: “The support received from existing and new high-quality investors demonstrates strong interest and confidence in Immutep’s clinical program. This financing provides funding certainty and significant growth opportunities for Immutep and I would like to thank existing shareholders for their continued support and welcome our new investors to the register.”
For more information, download the attached PDF.
Download this document